BiotechTube

Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ovarian Cancer Recurrent

Conditions

Ovarian Cancer Recurrent

Trial Timeline

Apr 15, 2025 → Mar 27, 2029

NCT ID
NCT06843447

About Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab

Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + Pembrolizumab is a phase 1/2 stage product being developed by Daiichi Sankyo for Ovarian Cancer Recurrent. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06843447. Target conditions include Ovarian Cancer Recurrent.

What happened to similar drugs?

11 of 20 similar drugs in Ovarian Cancer Recurrent were approved

Approved (11) Terminated (4) Active (7)
✅OlaparibAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved
✅Ganirelix acetateMerckApproved
✅Triptorelin 0.2 mgMerckApproved
✅Pegylated Liposomal Doxorubicin hydrochlorideMerckApproved
✅fosaprepitant + aprepitantMerckApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06843447Phase 1/2Recruiting

Competing Products

20 competing products in Ovarian Cancer Recurrent

See all competitors
ProductCompanyStageHype Score
mRNA-2416ModernaPhase 2
0
Doxorubicin Hydrochloride Liposome InjectionDr. Reddy's LaboratoriesPhase 1
26
azenosertibZentalis PharmaceuticalsPhase 2
32
Azenosertib + NiraparibZentalis PharmaceuticalsPhase 1/2
22
pemetrexed + topotecanEli LillyPhase 1
29
arzoxifene hydrochlorideEli LillyPhase 2
35
LY4337713Eli LillyPhase 1
36
PrexasertibEli LillyPhase 2
35
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabBioAtlaPhase 2
32
Gemcitabine + Oxaliplatin + BevacizumabEli LillyPhase 2
27
Trastzumab Deruxtecan + Bevacizumab + Platinum Based ChemotherapyDaiichi SankyoPhase 2
42
Trastuzumab Deruxtecan + BevacizumabDaiichi SankyoPhase 3
47
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
CS-1008 + Paclitaxel + CarboplatinDaiichi SankyoPhase 2
35
OSI-906 + PaclitaxelAstellas PharmaPhase 1/2
32
Enzalutamide 40 MGAstellas PharmaPhase 2
35
ASP0739Astellas PharmaPhase 1/2
24
IMAB027Astellas PharmaPhase 1
29
OSI-211 (Liposomal Lurtotecan)Astellas PharmaPhase 2
35